Company
Every investor coverage indicates participated in a round WE Buchan raised.
Companies WE Buchan acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
Stories naming WE Buchan. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Brisbane immunology company Kira Biotech has launched with a $20 million Series A, OneVentures leading alongside IP Group and Queensland government support, to progress its lead antibody KB312 into early human studies.
Medical device maker AirXpanders completed a private placement first announced in August 2018, issuing shares to Vivo Ventures and its chairman Barry Cheskin to raise about US$3.4 million, notifying the ASX accordingly.
Medical device maker AirXpanders appoints US industry veteran Frank Grillo as chief executive, succeeding interim leader Scott Murcray, with co-founder Barry Cheskin welcoming the hire ahead of Grillo fronting July's investor call.
AirXpanders' quarterly update: steady revenue, cost cuts and headcount reductions, Scott Murcray interim CEO while the board searches for a permanent chief, and a planned move to Australian distributors.
ASX-listed medical device maker AirXpanders, based in California, released its 2017 full-year results, reporting growing AeroForm sales, a US$34 million equity placement, and a US$15 million debt facility with Oxford Finance.
US-based medical device maker AirXpanders, listed on the ASX, proposes adding Liz Hammack to its board as co-founder Teddy Shalon departs and fellow director Dennis Condon faces re-election at its May annual meeting.
ASX-listed medical device maker AirXpanders, based in California, has committed investors for a A$45 million private placement at A$0.92 per CDI, with Canaccord Genuity as sole lead manager, to fund its US commercial launch.
Also GBS Ventures·GBS Ventures
Breast reconstruction device maker AirXpanders gained US regulator clearance for its needle-free AeroForm tissue expander, enabling a January 2017 American launch; an amended CE Mark also covers an enhanced version.
ASX-listed breast reconstruction device maker AirXpanders secured commitments for a 20 million dollar placement at 76 cents per CDI, and appointed Scott Murcray CFO/COO ahead of its planned US launch.